nodes	percent_of_prediction	percent_of_DWPC	metapath
Methamphetamine—obesity—polycystic ovary syndrome	0.782	1	CtDrD
Methamphetamine—SLC22A3—Metformin—polycystic ovary syndrome	0.117	1	CbGbCtD
Methamphetamine—SLC18A1—adrenal gland—polycystic ovary syndrome	0.00195	0.0614	CbGeAlD
Methamphetamine—SLC18A1—vagina—polycystic ovary syndrome	0.00181	0.0569	CbGeAlD
Methamphetamine—SLC18A1—endocrine gland—polycystic ovary syndrome	0.00169	0.0533	CbGeAlD
Methamphetamine—CYP2D6—urine—polycystic ovary syndrome	0.00109	0.0343	CbGeAlD
Methamphetamine—SLC18A2—endometrium—polycystic ovary syndrome	0.00077	0.0243	CbGeAlD
Methamphetamine—SLC22A3—embryo—polycystic ovary syndrome	0.00075	0.0236	CbGeAlD
Methamphetamine—SLC18A2—uterus—polycystic ovary syndrome	0.00071	0.0224	CbGeAlD
Methamphetamine—SLC18A2—adipose tissue—polycystic ovary syndrome	0.000694	0.0219	CbGeAlD
Methamphetamine—MAOB—embryo—polycystic ovary syndrome	0.000694	0.0219	CbGeAlD
Methamphetamine—SLC18A2—adrenal gland—polycystic ovary syndrome	0.000623	0.0196	CbGeAlD
Methamphetamine—MAOA—embryo—polycystic ovary syndrome	0.000592	0.0186	CbGeAlD
Methamphetamine—SLC18A2—vagina—polycystic ovary syndrome	0.000577	0.0182	CbGeAlD
Methamphetamine—MAOB—adrenal cortex—polycystic ovary syndrome	0.000569	0.0179	CbGeAlD
Methamphetamine—SLC22A3—endometrium—polycystic ovary syndrome	0.000549	0.0173	CbGeAlD
Methamphetamine—SLC18A2—endocrine gland—polycystic ovary syndrome	0.00054	0.017	CbGeAlD
Methamphetamine—MAOB—endometrium—polycystic ovary syndrome	0.000508	0.016	CbGeAlD
Methamphetamine—SLC22A3—adipose tissue—polycystic ovary syndrome	0.000494	0.0156	CbGeAlD
Methamphetamine—MAOA—adrenal cortex—polycystic ovary syndrome	0.000485	0.0153	CbGeAlD
Methamphetamine—MAOB—uterus—polycystic ovary syndrome	0.000468	0.0147	CbGeAlD
Methamphetamine—ADRA2C—adrenal cortex—polycystic ovary syndrome	0.000466	0.0147	CbGeAlD
Methamphetamine—Mephentermine—ADRA1A—polycystic ovary syndrome	0.000465	0.14	CrCbGaD
Methamphetamine—Lisdexamfetamine—ADRA1B—polycystic ovary syndrome	0.000462	0.139	CrCbGaD
Methamphetamine—MAOB—pituitary gland—polycystic ovary syndrome	0.000459	0.0145	CbGeAlD
Methamphetamine—MAOB—adipose tissue—polycystic ovary syndrome	0.000458	0.0144	CbGeAlD
Methamphetamine—SLC22A5—adrenal cortex—polycystic ovary syndrome	0.000447	0.0141	CbGeAlD
Methamphetamine—SLC22A3—adrenal gland—polycystic ovary syndrome	0.000444	0.014	CbGeAlD
Methamphetamine—MAOA—endometrium—polycystic ovary syndrome	0.000433	0.0136	CbGeAlD
Methamphetamine—ADRA2C—endometrium—polycystic ovary syndrome	0.000417	0.0131	CbGeAlD
Methamphetamine—SLC22A3—female gonad—polycystic ovary syndrome	0.000414	0.013	CbGeAlD
Methamphetamine—SLC22A3—vagina—polycystic ovary syndrome	0.000411	0.0129	CbGeAlD
Methamphetamine—MAOB—adrenal gland—polycystic ovary syndrome	0.00041	0.0129	CbGeAlD
Methamphetamine—MAOA—uterus—polycystic ovary syndrome	0.000399	0.0126	CbGeAlD
Methamphetamine—SLC22A5—endometrium—polycystic ovary syndrome	0.000399	0.0126	CbGeAlD
Methamphetamine—MAOA—pituitary gland—polycystic ovary syndrome	0.000392	0.0123	CbGeAlD
Methamphetamine—MAOA—adipose tissue—polycystic ovary syndrome	0.00039	0.0123	CbGeAlD
Methamphetamine—SLC22A3—endocrine gland—polycystic ovary syndrome	0.000385	0.0121	CbGeAlD
Methamphetamine—ADRA2C—uterus—polycystic ovary syndrome	0.000384	0.0121	CbGeAlD
Methamphetamine—MAOB—female gonad—polycystic ovary syndrome	0.000383	0.0121	CbGeAlD
Methamphetamine—MAOB—vagina—polycystic ovary syndrome	0.00038	0.012	CbGeAlD
Methamphetamine—SLC6A2—adrenal gland—polycystic ovary syndrome	0.00038	0.012	CbGeAlD
Methamphetamine—ADRA2C—pituitary gland—polycystic ovary syndrome	0.000377	0.0119	CbGeAlD
Methamphetamine—ADRA2C—adipose tissue—polycystic ovary syndrome	0.000375	0.0118	CbGeAlD
Methamphetamine—SLC6A4—endocrine gland—polycystic ovary syndrome	0.000374	0.0118	CbGeAlD
Methamphetamine—SLC22A5—pituitary gland—polycystic ovary syndrome	0.000361	0.0114	CbGeAlD
Methamphetamine—SLC22A5—adipose tissue—polycystic ovary syndrome	0.00036	0.0113	CbGeAlD
Methamphetamine—MAOB—endocrine gland—polycystic ovary syndrome	0.000356	0.0112	CbGeAlD
Methamphetamine—MAOA—adrenal gland—polycystic ovary syndrome	0.00035	0.011	CbGeAlD
Methamphetamine—ADRA2C—adrenal gland—polycystic ovary syndrome	0.000337	0.0106	CbGeAlD
Methamphetamine—ADRA2A—endometrium—polycystic ovary syndrome	0.000332	0.0105	CbGeAlD
Methamphetamine—SLC6A2—endocrine gland—polycystic ovary syndrome	0.00033	0.0104	CbGeAlD
Methamphetamine—MAOA—female gonad—polycystic ovary syndrome	0.000327	0.0103	CbGeAlD
Methamphetamine—MAOA—vagina—polycystic ovary syndrome	0.000325	0.0102	CbGeAlD
Methamphetamine—SLC22A5—adrenal gland—polycystic ovary syndrome	0.000323	0.0102	CbGeAlD
Methamphetamine—ADRA2C—female gonad—polycystic ovary syndrome	0.000314	0.00989	CbGeAlD
Methamphetamine—ADRA2C—vagina—polycystic ovary syndrome	0.000312	0.00983	CbGeAlD
Methamphetamine—ADRA2A—uterus—polycystic ovary syndrome	0.000306	0.00965	CbGeAlD
Methamphetamine—L-Phenylalanine—TH—polycystic ovary syndrome	0.000305	0.0917	CrCbGaD
Methamphetamine—MAOA—endocrine gland—polycystic ovary syndrome	0.000304	0.00957	CbGeAlD
Methamphetamine—ADRA2A—pituitary gland—polycystic ovary syndrome	0.000301	0.00947	CbGeAlD
Methamphetamine—SLC22A5—female gonad—polycystic ovary syndrome	0.000301	0.00947	CbGeAlD
Methamphetamine—ADRA2A—adipose tissue—polycystic ovary syndrome	0.0003	0.00944	CbGeAlD
Methamphetamine—SLC22A5—vagina—polycystic ovary syndrome	0.000299	0.00942	CbGeAlD
Methamphetamine—Dextroamphetamine—ADRA1B—polycystic ovary syndrome	0.000276	0.0828	CrCbGaD
Methamphetamine—ADRA2A—adrenal gland—polycystic ovary syndrome	0.000269	0.00846	CbGeAlD
Methamphetamine—ADRA2A—female gonad—polycystic ovary syndrome	0.000251	0.00789	CbGeAlD
Methamphetamine—Tolazoline—ADRA1A—polycystic ovary syndrome	0.00025	0.075	CrCbGaD
Methamphetamine—ADRA2A—vagina—polycystic ovary syndrome	0.000249	0.00784	CbGeAlD
Methamphetamine—Ephedrine—ADRA1A—polycystic ovary syndrome	0.000243	0.0731	CrCbGaD
Methamphetamine—ADRA2A—endocrine gland—polycystic ovary syndrome	0.000233	0.00734	CbGeAlD
Methamphetamine—Phenylpropanolamine—ADRA1A—polycystic ovary syndrome	0.000218	0.0656	CrCbGaD
Methamphetamine—CYP2D6—female gonad—polycystic ovary syndrome	0.000194	0.00611	CbGeAlD
Methamphetamine—Dextroamphetamine—ADRA1A—polycystic ovary syndrome	0.000186	0.0558	CrCbGaD
Methamphetamine—Pseudoephedrine—ADRA1A—polycystic ovary syndrome	0.000185	0.0554	CrCbGaD
Methamphetamine—CYP2D6—endocrine gland—polycystic ovary syndrome	0.00018	0.00568	CbGeAlD
Methamphetamine—Ephedrine—ADRB2—polycystic ovary syndrome	0.000145	0.0435	CrCbGaD
Methamphetamine—Benzphetamine—ADRA1A—polycystic ovary syndrome	0.000138	0.0413	CrCbGaD
Methamphetamine—Phenylpropanolamine—ADRB2—polycystic ovary syndrome	0.00013	0.039	CrCbGaD
Methamphetamine—Nateglinide—PPARG—polycystic ovary syndrome	0.000122	0.0365	CrCbGaD
Methamphetamine—Pseudoephedrine—ADRB2—polycystic ovary syndrome	0.00011	0.033	CrCbGaD
Methamphetamine—Benzyl alcohol—CYP1A1—polycystic ovary syndrome	9.57e-05	0.0287	CrCbGaD
Methamphetamine—ADRA2C—Signaling by GPCR—GHRL—polycystic ovary syndrome	1.11e-05	0.000166	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—HMMR—polycystic ovary syndrome	1.11e-05	0.000165	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—CYP19A1—polycystic ovary syndrome	1.1e-05	0.000165	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—INHBB—polycystic ovary syndrome	1.09e-05	0.000163	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—FST—polycystic ovary syndrome	1.09e-05	0.000163	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	1.08e-05	0.000162	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—ADRB3—polycystic ovary syndrome	1.07e-05	0.000161	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—RACGAP1—polycystic ovary syndrome	1.07e-05	0.00016	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—TEAD2—polycystic ovary syndrome	1.07e-05	0.00016	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—AKR1C2—polycystic ovary syndrome	1.07e-05	0.00016	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—LHB—polycystic ovary syndrome	1.06e-05	0.000159	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—HSD3B1—polycystic ovary syndrome	1.06e-05	0.000158	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—CYP1A1—polycystic ovary syndrome	1.05e-05	0.000157	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—AKR1C3—polycystic ovary syndrome	1.05e-05	0.000157	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—ADRA1A—polycystic ovary syndrome	1.04e-05	0.000156	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—GNRH1—polycystic ovary syndrome	1.04e-05	0.000155	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—CYP17A1—polycystic ovary syndrome	1.03e-05	0.000155	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—SULT2A1—polycystic ovary syndrome	1.03e-05	0.000154	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—IGF1—polycystic ovary syndrome	1.03e-05	0.000154	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—AKT2—polycystic ovary syndrome	1.03e-05	0.000153	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PDE3B—polycystic ovary syndrome	1.02e-05	0.000152	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—FST—polycystic ovary syndrome	1.02e-05	0.000152	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	1.01e-05	0.000151	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—AKR1C1—polycystic ovary syndrome	1e-05	0.00015	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—ADRB3—polycystic ovary syndrome	1e-05	0.00015	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—GNAS—polycystic ovary syndrome	1e-05	0.00015	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—RRM2—polycystic ovary syndrome	1e-05	0.000149	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—SCT—polycystic ovary syndrome	9.95e-06	0.000149	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—LHB—polycystic ovary syndrome	9.92e-06	0.000148	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—GHRL—polycystic ovary syndrome	9.91e-06	0.000148	CbGpPWpGaD
Methamphetamine—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—polycystic ovary syndrome	9.88e-06	0.000148	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—GNAS—polycystic ovary syndrome	9.85e-06	0.000147	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—ADRB2—polycystic ovary syndrome	9.82e-06	0.000147	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—MTHFR—polycystic ovary syndrome	9.8e-06	0.000146	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—SERPINE1—polycystic ovary syndrome	9.76e-06	0.000146	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—GNRH1—polycystic ovary syndrome	9.69e-06	0.000145	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—IL6—polycystic ovary syndrome	9.68e-06	0.000145	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—YAP1—polycystic ovary syndrome	9.64e-06	0.000144	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—LHB—polycystic ovary syndrome	9.63e-06	0.000144	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—IGF1—polycystic ovary syndrome	9.6e-06	0.000143	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—AKT2—polycystic ovary syndrome	9.59e-06	0.000143	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MTNR1B—polycystic ovary syndrome	9.49e-06	0.000142	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—HSD3B2—polycystic ovary syndrome	9.41e-06	0.000141	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—AKR1C1—polycystic ovary syndrome	9.39e-06	0.00014	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—NCOR1—polycystic ovary syndrome	9.38e-06	0.00014	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—GNAS—polycystic ovary syndrome	9.37e-06	0.00014	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—FGF18—polycystic ovary syndrome	9.33e-06	0.000139	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—SCT—polycystic ovary syndrome	9.29e-06	0.000139	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—NAMPT—polycystic ovary syndrome	9.27e-06	0.000138	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—FSHR—polycystic ovary syndrome	9.26e-06	0.000138	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—RBP4—polycystic ovary syndrome	9.25e-06	0.000138	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—ADRB2—polycystic ovary syndrome	9.17e-06	0.000137	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—CYP11A1—polycystic ovary syndrome	9.15e-06	0.000137	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—AKR1C1—polycystic ovary syndrome	9.12e-06	0.000136	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—SERPINE1—polycystic ovary syndrome	9.12e-06	0.000136	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—GNAS—polycystic ovary syndrome	9.11e-06	0.000136	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—POMC—polycystic ovary syndrome	9.06e-06	0.000135	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—GHRL—polycystic ovary syndrome	9e-06	0.000134	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PNPLA2—polycystic ovary syndrome	8.95e-06	0.000134	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—TH—polycystic ovary syndrome	8.95e-06	0.000134	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—CYP1A1—polycystic ovary syndrome	8.9e-06	0.000133	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MTNR1B—polycystic ovary syndrome	8.86e-06	0.000132	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—FGF18—polycystic ovary syndrome	8.71e-06	0.00013	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—SLC2A4—polycystic ovary syndrome	8.71e-06	0.00013	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—RACGAP1—polycystic ovary syndrome	8.7e-06	0.00013	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—AKR1C3—polycystic ovary syndrome	8.64e-06	0.000129	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—RBP4—polycystic ovary syndrome	8.64e-06	0.000129	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—YAP1—polycystic ovary syndrome	8.63e-06	0.000129	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—GAB1—polycystic ovary syndrome	8.51e-06	0.000127	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—CYP17A1—polycystic ovary syndrome	8.51e-06	0.000127	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—GNAS—polycystic ovary syndrome	8.51e-06	0.000127	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—SRD5A1—polycystic ovary syndrome	8.48e-06	0.000127	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ADRA1A—polycystic ovary syndrome	8.47e-06	0.000127	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—SULT2A1—polycystic ovary syndrome	8.39e-06	0.000125	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—MTHFR—polycystic ovary syndrome	8.29e-06	0.000124	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—VEGFA—polycystic ovary syndrome	8.27e-06	0.000124	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—FST—polycystic ovary syndrome	8.25e-06	0.000123	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	8.2e-06	0.000123	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—CYP19A1—polycystic ovary syndrome	8.18e-06	0.000122	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ADRB3—polycystic ovary syndrome	8.15e-06	0.000122	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—INSR—polycystic ovary syndrome	8.14e-06	0.000122	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—RRM2—polycystic ovary syndrome	8.13e-06	0.000121	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—STAR—polycystic ovary syndrome	8.09e-06	0.000121	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—YAP1—polycystic ovary syndrome	8.06e-06	0.00012	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—LHB—polycystic ovary syndrome	8.05e-06	0.00012	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—GAB1—polycystic ovary syndrome	7.95e-06	0.000119	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—PPARG—polycystic ovary syndrome	7.95e-06	0.000119	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—GNRH1—polycystic ovary syndrome	7.87e-06	0.000118	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—POMC—polycystic ovary syndrome	7.84e-06	0.000117	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—YAP1—polycystic ovary syndrome	7.83e-06	0.000117	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—IGF1—polycystic ovary syndrome	7.8e-06	0.000117	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—INS—polycystic ovary syndrome	7.8e-06	0.000116	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—AKT2—polycystic ovary syndrome	7.79e-06	0.000116	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—AKR1C3—polycystic ovary syndrome	7.74e-06	0.000116	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—AKR1C1—polycystic ovary syndrome	7.62e-06	0.000114	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TNRC6B—polycystic ovary syndrome	7.62e-06	0.000114	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—GNAS—polycystic ovary syndrome	7.61e-06	0.000114	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—INSR—polycystic ovary syndrome	7.6e-06	0.000114	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—SCT—polycystic ovary syndrome	7.55e-06	0.000113	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PGR—polycystic ovary syndrome	7.54e-06	0.000113	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—NAMPT—polycystic ovary syndrome	7.53e-06	0.000112	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—ADRB2—polycystic ovary syndrome	7.45e-06	0.000111	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CYP11A1—polycystic ovary syndrome	7.43e-06	0.000111	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—SERPINE1—polycystic ovary syndrome	7.4e-06	0.000111	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—TH—polycystic ovary syndrome	7.36e-06	0.00011	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—GNAS—polycystic ovary syndrome	7.31e-06	0.000109	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—AKR1C3—polycystic ovary syndrome	7.23e-06	0.000108	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—HMMR—polycystic ovary syndrome	7.21e-06	0.000108	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MTNR1B—polycystic ovary syndrome	7.2e-06	0.000108	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—SLC2A4—polycystic ovary syndrome	7.16e-06	0.000107	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TNRC6B—polycystic ovary syndrome	7.11e-06	0.000106	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—FGF18—polycystic ovary syndrome	7.08e-06	0.000106	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PGR—polycystic ovary syndrome	7.04e-06	0.000105	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—AKR1C3—polycystic ovary syndrome	7.02e-06	0.000105	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—RBP4—polycystic ovary syndrome	7.02e-06	0.000105	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PLAT—polycystic ovary syndrome	7.01e-06	0.000105	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—GHRL—polycystic ovary syndrome	7.01e-06	0.000105	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—NCOR1—polycystic ovary syndrome	6.96e-06	0.000104	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CYP17A1—polycystic ovary syndrome	6.91e-06	0.000103	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—GNAS—polycystic ovary syndrome	6.91e-06	0.000103	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—HSD3B1—polycystic ovary syndrome	6.88e-06	0.000103	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—POMC—polycystic ovary syndrome	6.75e-06	0.000101	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—CYP19A1—polycystic ovary syndrome	6.73e-06	0.000101	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—PPARG—polycystic ovary syndrome	6.72e-06	0.0001	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—VEGFA—polycystic ovary syndrome	6.71e-06	0.0001	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—ATF1—polycystic ovary syndrome	6.69e-06	9.99e-05	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—POMC—polycystic ovary syndrome	6.63e-06	9.91e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—CYP1A1—polycystic ovary syndrome	6.6e-06	9.86e-05	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—INS—polycystic ovary syndrome	6.6e-06	9.86e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—YAP1—polycystic ovary syndrome	6.55e-06	9.79e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—GHRL—polycystic ovary syndrome	6.55e-06	9.78e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PLAT—polycystic ovary syndrome	6.55e-06	9.78e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TCF7L2—polycystic ovary syndrome	6.52e-06	9.74e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—AKT2—polycystic ovary syndrome	6.49e-06	9.7e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—GAB1—polycystic ovary syndrome	6.46e-06	9.65e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—POMC—polycystic ovary syndrome	6.31e-06	9.42e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—LHB—polycystic ovary syndrome	6.28e-06	9.38e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—VEGFA—polycystic ovary syndrome	6.27e-06	9.37e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—ATF1—polycystic ovary syndrome	6.25e-06	9.33e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—INSR—polycystic ovary syndrome	6.18e-06	9.23e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—NGFR—polycystic ovary syndrome	6.17e-06	9.22e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—MTHFR—polycystic ovary syndrome	6.15e-06	9.19e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—HSD3B2—polycystic ovary syndrome	6.13e-06	9.17e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—POMC—polycystic ovary syndrome	6.13e-06	9.16e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PRL—polycystic ovary syndrome	6.11e-06	9.14e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TCF7L2—polycystic ovary syndrome	6.09e-06	9.1e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—AKT2—polycystic ovary syndrome	6.06e-06	9.06e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—GNAS—polycystic ovary syndrome	6.01e-06	8.98e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—TH—polycystic ovary syndrome	5.98e-06	8.93e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—AKR1C1—polycystic ovary syndrome	5.94e-06	8.88e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—AKT2—polycystic ovary syndrome	5.89e-06	8.81e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—AKR1C3—polycystic ovary syndrome	5.87e-06	8.77e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—SLC2A4—polycystic ovary syndrome	5.82e-06	8.69e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—ADRB2—polycystic ovary syndrome	5.8e-06	8.67e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TNRC6B—polycystic ovary syndrome	5.78e-06	8.63e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—NGFR—polycystic ovary syndrome	5.76e-06	8.61e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—POMC—polycystic ovary syndrome	5.73e-06	8.56e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—NCOR1—polycystic ovary syndrome	5.72e-06	8.55e-05	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—IL6—polycystic ovary syndrome	5.72e-06	8.55e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PGR—polycystic ovary syndrome	5.72e-06	8.55e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PRL—polycystic ovary syndrome	5.71e-06	8.53e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—AKT2—polycystic ovary syndrome	5.5e-06	8.23e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CYP19A1—polycystic ovary syndrome	5.47e-06	8.17e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—SULT2A1—polycystic ovary syndrome	5.47e-06	8.17e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—CYP1A1—polycystic ovary syndrome	5.43e-06	8.11e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—ADRB2—polycystic ovary syndrome	5.42e-06	8.1e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—GNAS—polycystic ovary syndrome	5.38e-06	8.04e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PLAT—polycystic ovary syndrome	5.32e-06	7.95e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—GHRL—polycystic ovary syndrome	5.32e-06	7.95e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—RRM2—polycystic ovary syndrome	5.3e-06	7.91e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—NCOR1—polycystic ovary syndrome	5.12e-06	7.66e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—POMC—polycystic ovary syndrome	5.12e-06	7.65e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—YAP1—polycystic ovary syndrome	5.1e-06	7.63e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—VEGFA—polycystic ovary syndrome	5.09e-06	7.61e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ATF1—polycystic ovary syndrome	5.07e-06	7.58e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—MTHFR—polycystic ovary syndrome	5.06e-06	7.56e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—NRG1—polycystic ovary syndrome	5.03e-06	7.52e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—GNAS—polycystic ovary syndrome	5.02e-06	7.51e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PPARG—polycystic ovary syndrome	4.99e-06	7.45e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	4.95e-06	7.39e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	4.92e-06	7.36e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—POMC—polycystic ovary syndrome	4.92e-06	7.35e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—NAMPT—polycystic ovary syndrome	4.9e-06	7.33e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—INS—polycystic ovary syndrome	4.89e-06	7.31e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—GNAS—polycystic ovary syndrome	4.88e-06	7.29e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CYP11A1—polycystic ovary syndrome	4.84e-06	7.24e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—NCOR1—polycystic ovary syndrome	4.79e-06	7.15e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—NRG1—polycystic ovary syndrome	4.7e-06	7.02e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NGFR—polycystic ovary syndrome	4.68e-06	7e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—POMC—polycystic ovary syndrome	4.65e-06	6.95e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—NCOR1—polycystic ovary syndrome	4.65e-06	6.95e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PRL—polycystic ovary syndrome	4.64e-06	6.93e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—AKR1C3—polycystic ovary syndrome	4.57e-06	6.83e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CYP17A1—polycystic ovary syndrome	4.5e-06	6.73e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—AKT2—polycystic ovary syndrome	4.47e-06	6.68e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CYP1A1—polycystic ovary syndrome	4.41e-06	6.59e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ADRB2—polycystic ovary syndrome	4.4e-06	6.58e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IRS2—polycystic ovary syndrome	4.31e-06	6.44e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—LEP—polycystic ovary syndrome	4.22e-06	6.3e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—MTHFR—polycystic ovary syndrome	4.11e-06	6.14e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PPARG—polycystic ovary syndrome	4.1e-06	6.13e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—GNAS—polycystic ovary syndrome	4.08e-06	6.1e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—POMC—polycystic ovary syndrome	4.05e-06	6.05e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IRS2—polycystic ovary syndrome	4.02e-06	6.01e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—INS—polycystic ovary syndrome	4.02e-06	6.01e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—LEP—polycystic ovary syndrome	3.94e-06	5.88e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—TH—polycystic ovary syndrome	3.9e-06	5.82e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.89e-06	5.81e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NRG1—polycystic ovary syndrome	3.82e-06	5.7e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	3.79e-06	5.66e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IRS1—polycystic ovary syndrome	3.76e-06	5.62e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—POMC—polycystic ovary syndrome	3.62e-06	5.41e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—INS—polycystic ovary syndrome	3.6e-06	5.38e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	3.56e-06	5.32e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IRS1—polycystic ovary syndrome	3.51e-06	5.25e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IGF1—polycystic ovary syndrome	3.48e-06	5.21e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—AKT2—polycystic ovary syndrome	3.48e-06	5.2e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—POMC—polycystic ovary syndrome	3.38e-06	5.06e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—INS—polycystic ovary syndrome	3.36e-06	5.03e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PPARG—polycystic ovary syndrome	3.33e-06	4.98e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.31e-06	4.94e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—POMC—polycystic ovary syndrome	3.29e-06	4.91e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IRS2—polycystic ovary syndrome	3.27e-06	4.88e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—INS—polycystic ovary syndrome	3.27e-06	4.88e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IGF1—polycystic ovary syndrome	3.25e-06	4.86e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—AKT2—polycystic ovary syndrome	3.25e-06	4.86e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—LEP—polycystic ovary syndrome	3.2e-06	4.78e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	3.18e-06	4.75e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.09e-06	4.62e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	3.03e-06	4.53e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	2.87e-06	4.29e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IRS1—polycystic ovary syndrome	2.85e-06	4.26e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—POMC—polycystic ovary syndrome	2.75e-06	4.11e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—INS—polycystic ovary syndrome	2.73e-06	4.08e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	2.68e-06	4e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—IL6—polycystic ovary syndrome	2.66e-06	3.98e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IGF1—polycystic ovary syndrome	2.64e-06	3.95e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—AKT2—polycystic ovary syndrome	2.64e-06	3.95e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.51e-06	3.75e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—IL6—polycystic ovary syndrome	2.49e-06	3.72e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.28e-06	3.4e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	2.17e-06	3.24e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	2.14e-06	3.2e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—INS—polycystic ovary syndrome	2.13e-06	3.18e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.13e-06	3.18e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—IL6—polycystic ovary syndrome	2.02e-06	3.02e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.73e-06	2.58e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IL6—polycystic ovary syndrome	1.57e-06	2.35e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IL6—polycystic ovary syndrome	1.47e-06	2.2e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IL6—polycystic ovary syndrome	1.19e-06	1.78e-05	CbGpPWpGaD
